Enliven Therapeutics (ELVN) Profit After Tax (2019 - 2026)
Enliven Therapeutics (ELVN) reported Profit After Tax of -$24.3 million for Q1 2026, up 14.72% on a YoY basis from -$21.2 million in Q1 2025, and up 17.17% sequentially from -$29.4 million in Q4 2025.
Enliven Therapeutics (ELVN) Profit After Tax (2019 - 2026) Analysis & Trends
Enliven Therapeutics (ELVN) has 8 years of Profit After Tax data on file, last reported at -$24.3 million in Q1 2026.
- For the quarter ending Q1 2026, Profit After Tax rose 14.72% year-over-year to -$24.3 million; the trailing twelve-month figure through Mar 2026 stood at -$99.2 million (down 4.42% YoY), and the FY2025 full-year result was -$103.4 million, down 16.05% from the prior year.
- Profit After Tax grew to -$24.3 million in Q1 2026, from -$29.4 million in the prior quarter.
- In the past five years, Profit After Tax ranged from a high of -$8.7 million in Q1 2022 to a low of -$29.4 million in Q4 2025.
- A 5-year average of -$19.2 million and a median of -$20.1 million in 2025 frame the typical range for Profit After Tax.
- Across the five-year window, Profit After Tax jumped 33.4% in 2022 and tumbled 101.29% in 2023, its largest moves.
- Tracing ELVN's Profit After Tax over 5 years: stood at -$9.5 million in 2022, then plunged by 101.29% to -$19.2 million in 2023, then fell by 21.56% to -$23.4 million in 2024, then decreased by 25.77% to -$29.4 million in 2025, then gained by 17.17% to -$24.3 million in 2026.
- Business Quant data shows ELVN's Profit After Tax at -$24.3 million in Q1 2026, -$29.4 million in Q4 2025, and -$20.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -36.84 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -65.60 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Enliven Therapeutics | 3.22 Bn | 3.22 Bn | - | -24.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -24.34 Mn |
| Dec 31, 2025 | -29.39 Mn |
| Sep 30, 2025 | -20.15 Mn |
| Jun 30, 2025 | -25.34 Mn |
| Mar 31, 2025 | -28.54 Mn |
| Dec 31, 2024 | -23.37 Mn |
| Sep 30, 2024 | -23.16 Mn |
| Jun 30, 2024 | -19.95 Mn |
| Mar 31, 2024 | -22.74 Mn |
| Dec 31, 2023 | -19.22 Mn |
| Sep 30, 2023 | -20.81 Mn |
| Jun 30, 2023 | -16.72 Mn |
| Mar 31, 2023 | -14.72 Mn |
| Dec 31, 2022 | -9.55 Mn |
| Sep 30, 2022 | -10.55 Mn |
| Jun 30, 2022 | -8.89 Mn |
| Mar 31, 2022 | -8.67 Mn |
| Dec 31, 2021 | -14.34 Mn |
| Sep 30, 2021 | -13.65 Mn |
| Jun 30, 2021 | -13.16 Mn |